Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on May 17, 2017, 10:31:33 am
-
A retooled version of the non-alcoholic steatohepatitis (NASH) drug FGF21, known as BMS-986036, showed promise in a recent Phase II trial, MedPage Today reports.
The Phase II trial included 74 people with NASH and mild to advanced fibrosis of the liver who received 16 weeks of one of three subcutaneous (injected under the skin) doses: a 10 milligram dose of BMS-986036 given every day, a 20 mg dose given every week, or a placebo given every day.
Findings were presented at the 52nd International Liver Congress in Amsterdam.
Read more...
https://www.hepmag.com/article/reconfigured-version-nash-drug-fgf21-improves-liver-health